Literature DB >> 2525063

Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.

C A Wilmot1, A M Szczepanik.   

Abstract

The effects of acute and chronic treatments with haloperidol or clozapine on the binding of [3H]spiperone to D2 and 5-HT2 receptors were examined in 6 discrete regions of the striatum, n. accumbens and frontal cortex using quantitative autoradiography. Acute treatment with haloperidol, 0.1-2.0 mg/kg, i.p., produced a dose-dependent reduction to 60% of control in the binding of [3H]spiperone to D2 receptors in the striatum and n. accumbens and no effect on the binding of [3H]spiperone to 5-HT2 receptors in the striatum, n. accumbens or frontal cortex. Acute treatment with clozapine, 10-40 mg/kg, i.p., produced a dose-dependent reduction in D2-specific binding in both the n. accumbens and the striatum and also significant reductions to 24% of control in the binding of [3H]spiperone to cortical 5-HT2 receptors. Chronic treatment with haloperidol, 1 mg/kg/day, i.p., significantly increased (40-65%) the maximal number of D2-specific [3H]spiperone binding sites in the n. accumbens and the dorsolateral and ventrolateral regions of the striatum, whereas small increases (20-29%) were seen in the ventromedial, dorsomedial, rostral and caudal regions of the striatum. Chronic treatment with clozapine, 20 mg/kg/day, i.p., did not change the maximal number of D2 receptors in the n. accumbens or any region of the striatum. Chronic treatments with clozapine produced a decrease in the maximal number of cortical 5-HT2 receptors to 55% of control whereas haloperidol had no effect. This study demonstrates regional differences in the up-regulation of striatal D2 receptors following chronic treatment with haloperidol and different effects of a typical and atypical neuroleptic on 5-HT2 receptors following acute and chronic treatments.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525063     DOI: 10.1016/0006-8993(89)90833-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

3.  State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia.

Authors:  Susan F Sonnenschein; Kathryn M Gill; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2018-09-18       Impact factor: 7.853

4.  Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients.

Authors:  R C Arora; H Y Meltzer
Journal:  J Neural Transm Gen Sect       Date:  1991

5.  High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET.

Authors:  A L Nordström; L Farde; C Halldin
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics.

Authors:  J G Csernansky; C T Wrona; M E Bardgett; T S Early; J W Newcomer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 7.  Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies.

Authors:  Rae Price; Bahar Salavati; Ariel Graff-Guerrero; Daniel M Blumberger; Benoit H Mulsant; Zafiris J Daskalakis; Tarek K Rajji
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-05-10       Impact factor: 5.067

8.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530

Review 9.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

10.  Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex.

Authors:  C K Meshul; A Janowsky; D E Casey; R K Stallbaumer; B Taylor
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.